Medical entities sent the Ministry of Health a new alert about the low stock of five medicines for hospital and pre-hospital use. The associations that sign the document ask the folder to help regulate the market.
In April, the Sheet had already shown that the folder was receiving alerts of low stock of injectable dipyrone in municipalities and hospitals.
The formal notices that month had been made by Conasems (National Council of Municipal Health Departments) and by six medical entities.
“We ratify our request, to respectfully request that coordinated actions be adopted in order to contribute to the regularity of the commercialization of medicines, in view of all the implications and clinical damages that the rupture of stock can cause”, said the entities.
Amib (Association of Brazilian Intensive Medicine), ISMP (Institute for Safe Practices in the Use of Medicines), Rebraensp (Brazilian Network of Nursing and Patient Safety), SBA (Brazilian Society of Anesthesiology), SBRAFH (Brazilian Society of Hospital Pharmacy and Health Services), Sobrasp (Brazilian Society for the Quality of Care and Patient Safety).
Erika Facundes, president of Amib’s pharmacy department, said that there are already hospital units —in Pernambuco, for example—with a shortage of medicines. The drugs on the list are dipyrone, neostigmine, atropine, amikacin and oxytocin. All are injectables.
“The industry’s justification was the reduction of the profit margin, arguing that it is no longer viable to produce the drug. The market is lacking and we are having difficulty buying”, he said.
Mauro Junqueira, executive secretary of Conasems, said that the bids remain empty.
“We made it clear [Ministério da Saúde] that we don’t want money because the purchase is our responsibility, the hospital and the municipality. We ask for support because we can’t buy it, it’s not on the market, it’s not available. Then you need regulation by the Ministry of Health,” he said.
The Ministry of Health, through a note, did not say what it would do to regulate the market.
The ministry said only that it works, together with Anvisa (National Health Surveillance Agency), municipal and state health councils and representatives of the pharmaceutical industries to verify the causes and articulate emergency actions to mitigate the shortage of medicines in the country.
In Brazil, prices are regulated by the CMED (Chamber of Regulation of the Medicines Market), which sets the limit at which a medicine can be marketed.
A CMED resolution, published in the Official Gazette, on June 1st, indicates that the problem may begin to be resolved in the coming days.
The Technical-Executive Committee will be responsible for drawing up a list of medicines at risk of shortages. The intention is to temporarily release the price adjustment of these drugs. The text enters into force ten days after publication.
Chad-98Weaver, a distinguished author at NewsBulletin247, excels in the craft of article writing. With a keen eye for detail and a penchant for storytelling, Chad delivers informative and engaging content that resonates with readers across various subjects. His contributions are a testament to his dedication and expertise in the field of journalism.
